Skin Cancer Charts Graphs: Fwd: The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 29, 2008 at 3:45 PM
Subject: The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour.
To: mesothelioma77@gmail.com

[1]Eur J Cancer. 2008 Mar 25;
Chabot I, Lelorier J, Blackstein ME

This paper examines the challenge of conducting economic evaluations to support patient access to cancer therapies when the cost-effectiveness estimation is hampered by crossover trial design. To demonstrate these limitations, we present the submission to the Canadian Drug Review (CDR) of a cost-effectiveness evaluation of sunitinib versus best supportive care (BSC) for the treatment of gastrointestinal stromal tumour in patients intolerant or resistant to imatinib. The economic model generated an incremental cost-effectiveness ratio for sunitinib versus BSC of $79,884/quality-adjusted life-year gained. Eight months after initial submission, CDR granted a final recommendation to fund sunitinib following the manufacturer's appeal against their first recommendation. Although cost-effectiveness is an important consideration in reimbursement decisions, there is a need for improved decision-making processes for cancer drugs, as well as a better understanding of the limitations of clinical trial design.

___
Source: http://www.hubmed.org/display.cgi?uids=18372169
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Skin Cancer Charts Graphs

Welcome to Skin cancer and Mesothelioma Cancer

Monday, March 31, 2008

Fwd: The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour.

About Me

More Tips and Info Sites

Blog Archive